Display options
Cite
Castañeda-Orjuela C, García-Molina M, De la Hoz-Restrepo F. Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?. Value Health Reg Issues. 2019;23:1-5doi: 10.1016/j.vhri.2019.09.009.
Castañeda-Orjuela, C., García-Molina, M., & De la Hoz-Restrepo, F. (2020). Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?. Value in health regional issues, 231-5. https://doi.org/10.1016/j.vhri.2019.09.009
Castañeda-Orjuela, Carlos, et al. "Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?." Value in health regional issues vol. 23 (2020): 1-5. doi: https://doi.org/10.1016/j.vhri.2019.09.009
Castañeda-Orjuela C, García-Molina M, De la Hoz-Restrepo F. Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?. Value Health Reg Issues. 2020 Dec;23:1-5. doi: 10.1016/j.vhri.2019.09.009. Epub 2019 Dec 24. PMID: 31881441.
Copy Download .nbib Format: NLM
Share it on

Value Health Reg Issues. 2020 Dec;23:1-5. doi: 10.1016/j.vhri.2019.09.009. Epub 2019 Dec 24.

Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?.

Value in health regional issues

Carlos Castañeda-Orjuela, Mario García-Molina, Fernando De la Hoz-Restrepo

Affiliations

  1. Epidemiology and Public Health Evaluation Group, Public Health Department, Universidad Nacional de Colombia, Bogotá, Colombia; Colombian National Health Observatory, Instituto Nacional de Salud, Bogotá, Colombia. Electronic address: [email protected].
  2. School of Economics, Universidad Nacional de Colombia, Bogotá, Colombia.
  3. Epidemiology and Public Health Evaluation Group, Public Health Department, Universidad Nacional de Colombia, Bogotá, Colombia.

PMID: 31881441 DOI: 10.1016/j.vhri.2019.09.009

Abstract

Healthcare costs are a concern for the sustainability of health systems in both rich and poor countries. Achieving a balance between the aspirations of payers and the manufacturers of new technologies is a challenge for democratic societies. Evidence about the efficacy and effectiveness of a new intervention is a fundamental aspect for its inclusion, but additional information about organization, implementation, and feasibility is required. Economic evaluations, especially cost-effectiveness analyses (CEA), help inform the choice of a particular health intervention, but they are not the only input for decision making (DM). Use of CEA is relatively recent but has quickly become widespread. CEA techniques have evolved into increasingly complex and sophisticated methods intended to reflect reality closely but, at the same time, their results have become more difficult to verify and validate. In developed countries, CEA results have generated intense debates, but in developing countries, these reflections are still weak due to lack of technical capacity. Competing perspectives on CEAs exist and can heavily influence the DM process. The use of CEAs and the interpretation of their results requires critical analysis, especially when public funds are to be invested. Here, we present a perspective on the use of CEAs for DM that arises from our experience of its use in developing countries and requires the consideration of other rationalities, in addition to the economic one, for DM.

Copyright © 2019 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc. All rights reserved.

Keywords: biomedical; cost-benefit analysis; decision making; public health; technology assessment

MeSH terms

Publication Types